Please login to the form below

Not currently logged in
Email:
Password:

carfilzomib

This page shows the latest carfilzomib news and features for those working in and with pharma, biotech and healthcare.

Amgen set for Kyprolis label boost after CHMP backing

Amgen set for Kyprolis label boost after CHMP backing

The Committee for Medicinal Products for Human Use (CHMP) has given the go-ahead for Amgen to add survival data to the labelling for its multiple myeloma treatment Kyprolis (carfilzomib).

Latest news

More from news
Approximately 5 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2013 Pharma deals during August 2013

    Indeed it is the fifth-largest biotechnology deal ever. The crown jewel Kyprolis (carfilzomib) is a proteasome inhibitor for the treatment of multiple myeloma which was launched in 2012 and has ... In 2012 these drugs generated $289.6m in revenue for Onyx

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics